Kenneth S. Shindler, M.D., Ph.D.
F.M Kirby Associate Professor of Ophthalmology
Medical Staff Physician, Hospital of the University of Pennsylvania
Medical Staff Physician, Penn Presbyterian Medical Center
Member, Institute for Translational Medicine and Therapeutics
Member, Institute for Immunology
Director, Neuro-Ophthalmology Fellowship, University of Pennsylvania
Department: Ophthalmology
Contact information
Scheie Eye Institute
51 North 39th Street
Philadelphia, PA 19104
51 North 39th Street
Philadelphia, PA 19104
Graduate Group Affiliations
Publications
Education:
ScB (Biochemistry)
Brown University, Providence, 1991.
MD, PhD (Medicine/Neuroscience)
Washington University, St. Louis, 1999.
ScB (Biochemistry)
Brown University, Providence, 1991.
MD, PhD (Medicine/Neuroscience)
Washington University, St. Louis, 1999.
Post-Graduate Training
Transitional Internship, Presbyterian Medical Center, Philadelphia, PA, 1999-2000.
Ophthalmology Residency, University of Pennsylvania, 2000-2003.
Neuro-Ophthalmology Fellowship, University of Pennsylvania, 2003-2004.
Transitional Internship, Presbyterian Medical Center, Philadelphia, PA, 1999-2000.
Ophthalmology Residency, University of Pennsylvania, 2000-2003.
Neuro-Ophthalmology Fellowship, University of Pennsylvania, 2003-2004.
Certifications
American Board of Ophthalmology, 2005.
Permanent linkAmerican Board of Ophthalmology, 2005.
Description of Research Expertise
Dr. Shindler's research is examining potential mechanisms to provide neuroprotection of retinal ganglion cells in optic neuritis. Optic neuritis is an inflammatory disease of the optic nerve that often occurs as part of the neurodegenerative disease multiple sclerosis. Damage to nerve cells can lead to permanent vision loss in these patients. Dr. Shindler's studies are helping to identify new therapies to prevent nerve damage in this disease, and such therapies will also likely have benefits for other neurodegenerative diseases as well.Keywords
Neuro-ophthalmologic conditions, including optic neuropathies, papilledema, and binocular double vision
Description of Clinical Expertise
Neuro-ophthalmology. Dr. Shindler treats patients with neuro-ophthalmologic conditions, including optic neuropathies, papilledema, and binocular double vision.Selected Publications
McDougald DS, Dine KE, Zezulin AU, Bennett J, Shindler KS: SIRT1 and NRF2 Gene Transfer Mediate Distinct Neuroprotective Effects Upon Retinal Ganglion Cell Survival and Function in Experimental Optic Neuritis. Invest. Ophthalmol. Vis. Sci. 59: 1212-1220, Mar 2018.Grinblat GA, Khan RS, Dine K, Wessel H, Brown L, Shindler KS: RGC Neuroprotection Following Optic Nerve Trauma Mediated By Intranasal Delivery of Amnion Cell Secretome. Invest. Ophthalmol. Vis. Sci. 59: 2470-2477, May 2018.
Khan RS, Dine K, Bauman B, Lorentsen M, Lin L, Brown H, Hanson LR, Svitak AL, Wessel H, Brown L, Shindler KS: Intranasal Delivery of A Novel Amnion Cell Secretome Prevents Neuronal Damage and Preserves Function In A Mouse Multiple Sclerosis Model. Sci. Rep. 7: 41768, Jan 2017.
Khan RS, Dine K, Das Sarma J, Shindler KS : SIRT1 activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease Acta Neuropathol. Commun. 2(1): 3, Jan 2014.
Zuo L, Khan RS, Lee V, Dine K, Wu W, Shindler KS: SIRT1 promotes RGC survival and delays loss of function following optic nerve crush. Invest. Ophthalmol. Vis. Sci. 54(7): 5097-102, Jul 2013.
Chen Y, Khan RS, Cwanger A, Song Y, Steenstra C, Bang S, Cheah JH, Dunaief J, Shindler KS, Snyder SH, Kim SF: Dexras1, a small GTPase, is required for glutamate-NMDA neurotoxicity J. Neurosci. 33(8): 3582-7, Feb 2013.
Fonseca-Kelly Z, Nassrallah M, Uribe J, Khan RS, Dine K, Dutt M, Shindler KS: Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front. Neurol. 3: 84, May 2012.
Shindler KS, Chatterjee D, Biswas K, Goyal A, Dutt M, Nassrallah M, Khan RS, Das Sarma J: Macrophage-mediated optic neuritis induced by retrograde axonal transport of spike gene recombinant mouse hepatitis virus. J. Neuropathol. Exp. Neurol. 70(6): 470-80, June 2011.
Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A: Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J. of Neuro-Ophthalmol. 30(4): 328-39, Dec 2010.
Das Sarma J, Kenyon LC, Hingley ST, Shindler KS: Mechanisms of primary axonal damage in a viral model of multiple sclerosis J. Neurosci. 29(33): 10272-10280, Aug 2009.